Resverlogix Corp. (TSE:RVX – Get Free Report) shares traded up 16.7% on Wednesday . The stock traded as high as C$0.07 and last traded at C$0.07. 197,830 shares were traded during mid-day trading, an increase of 225% from the average session volume of 60,927 shares. The stock had previously closed at C$0.06.
Resverlogix Trading Down 7.1 %
The firm has a market capitalization of C$18.00 million, a PE ratio of -1.30 and a beta of 0.71. The firm has a 50-day moving average of C$0.07 and a two-hundred day moving average of C$0.06.
Resverlogix (TSE:RVX – Get Free Report) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported C($0.02) earnings per share for the quarter. Equities research analysts expect that Resverlogix Corp. will post -0.22 earnings per share for the current fiscal year.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Resverlogix
- ETF Screener: Uses and Step-by-Step Guide
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Conference Calls and Individual Investors
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What is the NASDAQ Stock Exchange?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
